ARTICLE
|
doi:10.20944/preprints202301.0421.v3
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
Oncology; Immune Checkpoint Inhibition; PD-1; PD-L1; CTLA-4; Immune Related Adverse Events; Immunotherapy; Tumor Plasticity; Tumor Microenvironment; Optimum Therapy Duration
Online: 6 March 2023 (01:53:16 CET)